KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bausch Health Companies (BHC) EBIT (2016 - 2025)

Bausch Health Companies (BHC) has disclosed EBIT for 17 consecutive years, with $474.0 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 15.05% to $474.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.8 billion through Dec 2025, up 17.27% year-over-year, with the annual reading at $1.8 billion for FY2025, 17.27% up from the prior year.
  • EBIT hit $474.0 million in Q4 2025 for Bausch Health Companies, down from $619.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $619.0 million in Q3 2025 to a low of -$270.0 million in Q2 2021.
  • Historically, EBIT has averaged $261.3 million across 5 years, with a median of $301.5 million in 2022.
  • Biggest YoY gain for EBIT was 7440.0% in 2021; the steepest drop was 900.0% in 2021.
  • Year by year, EBIT stood at $367.0 million in 2021, then crashed by 164.31% to -$236.0 million in 2022, then skyrocketed by 253.39% to $362.0 million in 2023, then skyrocketed by 54.14% to $558.0 million in 2024, then fell by 15.05% to $474.0 million in 2025.
  • Business Quant data shows EBIT for BHC at $474.0 million in Q4 2025, $619.0 million in Q3 2025, and $444.0 million in Q2 2025.